论文部分内容阅读
目的观察阿奇霉素治疗小儿支原体肺炎的临床疗效与安全性。方法将支原体肺炎患儿86例随机分对照组、治疗组,均给予基础、对症治疗等;对照组加用红霉素,治疗组加用阿奇霉素。结果治疗组临床疗效明显优于对照组(P<0.05);治疗组在临床症状与体征及平均住院时间等方面均优于对照组,差异有统计学意义(P<0.05);胃肠道反应发生率明显低于对照组。结论阿奇霉素治疗支原体肺炎疗效确切且不良反应少,值得临床推广。
Objective To observe the clinical efficacy and safety of azithromycin in treating children with mycoplasma pneumonia. Methods Eighty-six children with mycoplasmal pneumonia were randomly divided into control group and treatment group, all of whom were given basic and symptomatic treatment. The control group was given erythromycin and the treatment group was given azithromycin. Results The clinical efficacy of the treatment group was significantly better than that of the control group (P <0.05). The treatment group was superior to the control group in clinical symptoms and signs and the average length of stay, the difference was statistically significant (P <0.05) The incidence was significantly lower than the control group. Conclusion Azithromycin treatment of mycoplasma pneumonia is effective and less adverse reactions, is worth clinical promotion.